Progenics completes rolling Azedra NDA

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) completed rolling submission of an NDA to FDA for Azedra iobenguane I 131 (Ultratrace I-131-MIBG, Ultratrace iobenguane I 131) to treat malignant recurren...